Fairer financing of vaccines in a world living with COVID-19 by Megiddo, Itamar et al.
 1Megiddo I, et al. BMJ Global Health 2020;5:e002951. doi:10.1136/bmjgh-2020-002951
Fairer financing of vaccines in a world 
living with COVID-19
Itamar Megiddo   ,1 Justice Nonvignon,2 Richmond Owusu,2 Kalipso Chalkidou,3,4 
Abigail Colson,1 Mohamed Gad,3 Petra Klepac,5,6 Francis Ruiz,3,4 Alec Morton1
Commentary
To cite: Megiddo I, Nonvignon J, 
Owusu R, et al. Fairer financing 
of vaccines in a world living with 
COVID-19. BMJ Global Health 
2020;5:e002951. doi:10.1136/
bmjgh-2020-002951
Handling editor Seye Abimbola
Received 19 May 2020
Revised 25 June 2020
Accepted 28 June 2020
1Department of Management 
Science, University of 
Strathclyde, Glasgow, UK
2School of Public Health, 
University of Ghana, Legon, 
Ghana
3Global Health Development 
group, Imperial College London 
School of Public Health, London, 
UK
4Center for Global Development 
Europe, Washington, London, UK
5Centre for the Mathematical 
Modelling of Infectious 
Diseases, Department of 
Infectious Disease Epidemiology, 
LSHTM, London, UK
6Department of Applied 
Mathematics and Theoretical 
Physics, University of 
Cambridge, Cambridge, UK
Correspondence to
Dr Itamar Megiddo;  
 itamar. megiddo@ strath. ac. uk
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY. 
Published by BMJ.
The COVID-19 pandemic underscores that 
infectious disease is a global challenge. For 
many infectious diseases, vaccines are the 
best tools available for control and elimina-
tion. Vaccines helped eliminate smallpox 
and reduce annual measles deaths from 
2.6 million before widespread vaccination 
to 140 000 in 2018.1 Vaccines avert two to 
three million deaths annually, and they are 
often touted as one of the most cost- effective 
health interventions.1 Since infectious 
diseases do not recognise borders, vaccine 
deployment requires global cooperation to 
achieve the best outcomes.
Presently, many countries have halted 
vaccination programmes and campaigns, 
including for measles and polio, where vacci-
nation has had transformative impact on 
the burden of disease. Gavi estimates that at 
least 13.5 million people are missing vacci-
nations, and that will rise as the pandemic 
continues.2 Hence, the burden of vaccine- 
preventable diseases will increase as a conse-
quence of COVID-19: this is especially true 
in low- income and middle- income countries 
(LMICs), which already suffer from a greater 
infectious disease burden than high- income 
countries and where the pandemic could, 
as elsewhere, overwhelm health systems that 
have a lower capacity. Sustaining routine vacci-
nation programmes in Africa, for example, 
is estimated to prevent 140 deaths for every 
excess COVID-19 death attributable to severe 
acute respiratory syndrome coronavirus 2 
(SARS- CoV-2) infections acquired during the 
routine vaccination visits.3
Uncertainties loom over future vaccine 
financing, as the postpandemic outlook for 
development assistance for health (DAH) is 
unclear. LMICs and global funders must trade 
off between increasing vaccination coverage, 
continuing disease elimination campaigns 
and introducing new, more expensive 
vaccines. A vaccine for SARS- CoV-2 has huge 
potential to alleviate death and suffering, but 
without increased DAH, its deployment could 
also exacerbate financial pressures on health 
systems. Further, though we have not seen 
COVID-19 cases overwhelm health system 
capacity across LMICs at the time of writing, 
we have seen global fiscal contraction, and this 
could negatively affect DAH and funding of 
health systems and vaccination programmes 
in LMICs. Global cooperation and wise prior-
itisation are important for the sustainability of 
vaccination programmes and to avoid resur-
gence of diseases already controlled in many 
places.
The science is clear that high- income 
country funding for vaccines in LMICs is 
both indispensable and in the interest of 
high- income countries themselves. Klepac 
et al4 explore local and global vaccination 
strategies in an integrated susceptible–
infected–recovered game- theoretic model. 
They show in a model with identical coun-
tries that a global optimum is reached when 
countries cooperate and do not impose travel 
restrictions: countries achieve higher vacci-
nation coverage (and hence lower disease 
Summary box
 ► The COVID-19 pandemic has disrupted routine and 
campaign- based vaccination, potentially increasing 
the future vaccine- preventable disease burden and 
threatening to overwhelm health systems.
 ► Vaccine- preventable diseases are transboundary 
problems that require global cooperation to achieve 
the best outcomes.
 ► Investments, predominantly by rich countries—in 
effect transfers to poor countries—are required as 
part of the financing solution. Theoretical advances 
show how such funds can be operationally priori-
tised and disbursed equitably. Such transfers are 
also in the interest of high- income countries, and co-
operation achieves better outcomes than strategies 
such as travel restrictions for vaccine- preventable 
diseases.
 ► Similar cooperation and financing issues will arise if 
and when it is time to distribute a COVID-19 vaccine.
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prevalence) at a lower cost working together than on 
their own. Further, when countries are economically or 
epidemiologically different, countries that are better off 
benefit from investing in vaccination in connected coun-
tries with a higher burden by reducing imported cases 
from other countries.4 In both of these cases, by acting 
together, countries achieve better outcomes (lower prev-
alence and higher vaccination coverage) at a lower cost 
than by acting alone.
Even if the global community rises to the challenge 
of cooperation, and even if funds for vaccine deploy-
ment are raised, how should money be prioritised and 
disbursed? Prioritisation must be principled and demon-
strably equitable while maintaining immunisation 
programmes’ sustainability in light of other financial 
pressures. The donor–country (DC) model proposed by 
Morton et al5 is relevant.5 Conventional health economics 
practice for a single decision- maker allocating funds in a 
single country suggests we invest in the most cost- effective 
interventions.6 However, in a multiactor environment, 
Morton et al5 demonstrate that to achieve the greatest 
benefits from donors’ funds, cost- effective interven-
tions—ones below a cost- effectiveness threshold—should 
be financed domestically. Donors should avoid crowding 
out domestic financing by prioritising cofinancing inter-
ventions that are only just cost- ineffective, reducing these 
interventions’ costs to the point of cost- effectiveness from 
the country perspective.
Gavi is the main distributor of vaccine- specific donor 
funding, contributing US$1.52 billion in 2018 (54% 
of donor vaccine- funding),7 and Gavi’s aid has helped 
increase vaccination coverage.8 Gavi’s aim is for partner 
countries to achieve financial and programmatic inde-
pendence that sustains high immunisation coverage.9 
To achieve this goal, Gavi also supports health system 
strengthening, which is particularly important because 
vaccine costs purport only a small proportion of the 
funds required for vaccine delivery. Sustainable country 
vaccination programmes require strong institutions and 
delivery systems. Gavi’s innovative cofinancing policy, 
which embodies the idea that countries should transi-
tion towards self- sufficiency as their wealth increases, is 
a core part of its approach to sustainability. However, the 
policy is based on rules that, though transparent, seem 
ad hoc, have no theoretical underpinnings and do not 
clearly lead to an equitable allocation. Further, financial 
and institutional sustainability remain challenges for 
many graduating countries10—an issue the pandemic 
may exacerbate.
Our recent study, Analysis of Interventions in Develop-
ment Aid (AIDA) reviewed information on cofinancing of 
vaccines in Ghana and comparator countries.11 Figure 1 
shows suggested diphtheria, tetanus, pertussis and hepa-
titis B vaccine cofinancing in Ghana according to the DC 
model using costing evidence from a cost- effectiveness 
study (figure 1A)12 and cofinancing in practice according 
to Gavi country progress reports (figure 1B).9 Two imme-
diate observations stand out. First, the DC model suggests 
the transition to self- sufficiency should be gradual, 
though, in practice, it seems sporadic. This inconsis-
tency in cofinancing is evident for comparator countries 
across time, when comparing the per cent of the vaccine 
financed by Gavi to gross national income per capita 
(figure 1C). Second, the costs derived from the cost- 
effectiveness study are higher than the vaccine progress 
report since the study accounts for costs such as training 
and social mobilisation that are not included in the 
reports. The discrepancy further emphasises the impor-
tance of Gavi’s health system strengthening initiative, 
which is not accounted for in vaccine- specific financing 
reports, and further research on how this funding is 
distributed is needed.
Based on our findings, we argue that Gavi cofinancing 
policy should be underpinned by an explicit norma-
tive model—such as the DC model in Morton et al5—to 
ensure equity between member countries and account-
ability to funders. The model should be flexible to adjust 
for unexpected events such as the COVID-19 pandemic. 
Countries would transition towards self- sufficiency as 
their wealth (and thus their cost- effectiveness threshold) 
increases. Implementing such a model requires trans-
parent cost- effectiveness studies that provide complete 
descriptions and presentation of costs, allowing repro-
ducibility from different stakeholder perspectives, a 
point highlighted by AIDA stakeholders. The DC model, 
in particular, also requires cost- effectiveness threshold 
data, which are increasingly estimated in recent years.13–15 
AIDA stakeholders also provided valuable insights on 
how such theoretic models can be adapted for use in a 
real development setting. For example, they highlighted 
that disease burden, and thus population health and 
budget impact, are important for vaccine financing deci-
sions and so should be explicitly included in the country 
decision problem in the likes of the Morton et al model.11 
These aspects are important from the donors’ perspec-
tives if donors aim to include sustainability and equity, 
and, before transitioning countries out of aid, donors 
should be more aligned with local processes that promote 
sustainability. More research is needed on how to incor-
porate factors that define which countries have the 
greatest need (eg, financial and institutional capacity) in 
or alongside a normative model. Defining these factors 
will require further stakeholder engagement.
Many of the same arguments are true for developing 
and distributing a COVID-19 vaccine, though the models 
we discuss here do not explicitly consider vaccine devel-
opment. A cooperative multiactor approach is also salient 
for vaccine development, distributing the risks and costs 
to accelerate the process in outbreak situations. A coordi-
nated, international and intergovernmental plan is espe-
cially important for new epidemics such as the COVID-19 
pandemic. In 2017, the Coalition for Epidemic Prepared-
ness Innovation was launched precisely to fill this gap—
as a public, private and philanthropic partnership—and 
so we have seen encouraging cooperation in this space. 
Nonetheless, if and once we have a vaccine available, we 
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Figure 1 DTP- HepB vaccination cofinancing in Ghana and comparator countries. (A) Donor–country model suggested 
cofinancing split of domestic country and donor cofinancing of the DTP- HepB vaccine (diphtheria, tetanus, pertussis and 
hepatitis B) in Ghana using costing evidence from Levin et al.5 11 12; (B) Actual split of domestic country and Gavi financing 
based on Gavi country progress reports between 2006 and 2016 (no data were available for 2015).16 (C) Per cent of Gavi 
contribution towards cofinancing compared with GNI per capita for comparator countries between 2012 and 2016,16 for 
different year and country observations and the size representing total funds for the vaccine. DTP- HepB, diphtheria, tetanus, 
pertussis and hepatitis B; GNI, gross national income.
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will need to distribute it in a manner that effectively and 
efficiently alleviates the burden of COVID-19 globally 
while doing so in an equitable manner and using the 
health systems we have available at the time.
Defeating the world’s vaccine- preventable diseases 
requires cooperation, but without fairness, cooperation 
cannot be sustained. Recent theoretic advances show 
why rich–poor financial transfers will be required as part 
of any financing solution, and also how such funds can 
be operationally prioritised and disbursed equitably. 
Contextualising studies such as AIDA are an important 
next- stage priority to show how these ideas can be imple-
mented in practice for specific vaccine programmes and 
in specific country settings.
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